



US Value & Access

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

February 1, 2023

To: The Office of the Attorney General of Vermont

Via: Electronic Mail (AGO.DrugCosts@vermont.gov ; AGO.highcostprescriptiondrugs@vermont.gov)

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637 (b)

Amgen Inc, USA (Amgen) hereby submits this information pursuant 18 V.S.A § 4637 (b):

On January 31, 2023 Amgen released the following specialty drug to the commercial market:

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesaler Acquisition Cost, as of the date of commercial availability)
AMJEVITA (20 mg/0.4 mL prefilled syringe, 1 pk)	55513-0411-01	31-Jan-23	\$3,288.24
AMJEVITA (40 mg/0.8 mL prefilled syringe, 1 pk)	55513-0410-01	31-Jan-23	\$3,288.24
AMJEVITA (40 mg/0.8 mL Autoinjector, 1 pk)	55513-0400-01	31-Jan-23	\$3,288.24
AMJEVITA (40 mg/0.8 mL Autoinjector, 2 pk)	55513-0400-02	31-Jan-23	\$6,576.48
AMJEVITA (40 mg/0.8 mL Autoinjector, 1 pk)	72511-0400-01	31-Jan-23	\$1,557.59
AMJEVITA (40 mg/0.8 mL Autoinjector, 2 pk)	72511-0400-02	31-Jan-23	\$3,115.18

Amgen provides this report consistent with its understanding and interpretation of 18 V.S.A § 4637 and its provisions. In providing this report, Amgen does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Amgen or any of its affiliates, now or in the future. Amgen, on behalf of itself and its affiliates, expressly reserves all such rights.

Regards,

Pat Costello
Executive Director, US Value and Access Strategy
Amgen Inc., USA